Mesoblast Limited (MESO) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Mesoblast Limited  (NASDAQ: MESO)

Mesoblast Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Mesoblast Limited in the fourth quarter 2025?
Mesoblast Limited recorded a cumulative net loss of $-102 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -18.16%.

Within the Biotechnology & Pharmaceuticals industry 23 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 2653 to 2953.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
IV. Quarter
Y / Y Equity Change 24.59 % 24.38 % -4.28 % 24.38 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -102 -88 -88 -88 -88
Return On Equity (TTM) -18.16 % -16.47 % -17.42 % -17.24 % -18.29 %
MESO's Total Ranking # 2953 # 2653 # # #
Equity (TTM) in Millions 575 597 480 597 461
Seq. Equity Change -3.81 % 24.38 % -19.6 % 29.52 % -3.97 %
Seq. Net Income Change - - - - -

Back to MESO Management Effectiveness >> MESO's 5 Years Annual ROE >> Compare MESO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 24
Sector # 269
Overall # 2953

Return On Equity Statistics
High Average Low
-3.12 %
-8.41 %
-18.29 %
0   (Jun 30 2024)





MESO Annual Return On Equity (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022		 (Jun 30 2021)
2021
Total Equity in Millions 597 480 502 497 581
Y / Y Equity Change 24.38 % -4.28 % 0.96 % -14.51 % 5.84 %
Net Income in Millions -102 -88 -82 -91 -99
Y / Y Net Income Change - - - - -
Return On Equity -17.1 % -18.31 % -16.32 % -18.38 % -17 %

Back to MESO Management Effectiveness >> MESO's 5 Years Annual ROE >> Compare MESO ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MESO's' Return on Equity at Yahoo Finance
MESO's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MESO's Competitors
Subscribers only: Roe for Mesoblast Limited's Suppliers
Subscribers only: Return On Equity for MESO's Customers




Companies with similar Return On Equity at Jun 30 2025, within Healthcare Sector ROE

Date modified: 2026-07-07T12:24:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.